ClinicalTrials.Veeva

Menu

Triamcinolone or Bevacizumab for Central Retinal Vein Occlusion With Poor Vision

H

Hallym University

Status

Completed

Conditions

Central Retinal Vein Occlusion With 20/200 or Worse Visual Acuity

Treatments

Procedure: intravitreal injection

Study type

Interventional

Funder types

Other

Identifiers

NCT01053858
2009_10_12

Details and patient eligibility

About

To evaluate the effect of intravitreal bevacizumab with intravitreal triamcinolone for the treatment of central retinal vein occlusion (CRVO) presenting poor visual acuity.

Enrollment

38 patients

Sex

All

Ages

20+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • central macular thickness of more than 250 μm and baseline visual acuity of 20/200 or worse than 20/200 in patient with central retinal vein occlusion

Exclusion criteria

  • previous treatment such as intravitreal injection, subtenon injection, or laser photocoagulation since the time of onset
  • Patients with a history of glaucoma, neovascular glaucoma, diabetic retinopathy, and macular disorders
  • neovascularization on the disc or elsewhere or rubeosis

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

38 participants in 2 patient groups

bevacizumab
Active Comparator group
Description:
intravitreal bevacizumab or triamcinolone determined by single physician
Treatment:
Procedure: intravitreal injection
triamcinolone
Active Comparator group
Treatment:
Procedure: intravitreal injection

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems